CKF Tide Tables

MGF (PEG-MGF)

Quick Facts

PropertyValue
CategoryGrowth Factor Peptide
Risk LevelExperimental
AdministrationSubcutaneous Injection
Typical Frequency2–3 Times Weekly
Estimated Half-LifeExtended Long-Acting Peptide
Primary Research InterestRecovery / Muscle Repair / Systemic Growth Signaling
Important Disclaimer

This material is provided strictly for educational and informational purposes related to peptide research and experimental growth-factor compounds. PEG-MGF is a biologically active pegylated IGF-1 splice variant associated with tissue repair and muscle recovery signaling pathways. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.

1. Reconstitution Guide

  • Vial Size: 2 mg
  • Dilutant Type: BAC Water
  • Amount of Dilutant Added: 2 mL
  • Final Concentration: 1.00 mg/mL

At this concentration:
• 200 mcg = 0.200 mL (20.0 units)
• 500 mcg = 0.500 mL (50.0 units)

2. Route of Administration

PEG-MGF is most commonly administered as a post-workout subcutaneous injectable growth-factor peptide.

  • Primary Route: SubQ Injection
  • Preferred Timing: Post-workout preferred
  • Administration Notes: Frequently researched alongside resistance training and recovery-focused protocols

3. Typical Research Protocols

  • Product Strength: 1.00 mg/mL
  • Typical Delivered Amount: 200–500 mcg
  • Frequency: 2–3 times weekly
  • Cycle Length: 4–12 weeks on / 4–12 weeks off
  • Special Notes: Unlike Standard MGF, PEG-MGF is pegylated to dramatically extend its half-life and allow for more prolonged systemic activity rather than extremely short-lived localized signaling. Because of this extended duration, researchers typically use PEG-MGF less frequently and often emphasize spacing doses several days apart. Post-workout administration is still commonly preferred, though the peptide is generally discussed as less timing-sensitive than Standard MGF. As with other experimental growth-factor peptides, conservative dosing and periodic cycling are commonly emphasized due to limited long-term human safety data and theoretical concerns regarding excessive growth signaling.

4. Summary

PEG-MGF is an experimental pegylated IGF-1 splice variant researched for its potential effects on muscle repair, recovery enhancement, systemic growth signaling, and adaptation to resistance training.

Research interest in PEG-MGF commonly centers around prolonged recovery signaling, tissue-repair pathways, and training adaptation research.

5. Mechanism of Action

PEG-MGF is believed to function as a pegylated mechanically induced IGF-1 splice variant involved in tissue repair and muscle adaptation signaling.

  • Muscle repair signaling
  • Recovery pathway activation
  • Potential satellite-cell support
  • Systemic adaptation signaling
  • Training-response modulation
  • Extended-duration growth-factor activity

Pegylation substantially prolongs peptide duration compared to Standard MGF.

6. Potential Benefits

  • Potential enhancement of recovery signaling
  • Possible improvement in training adaptation
  • Potential muscle repair support
  • Systemic recovery applications
  • Possible synergistic effects with resistance training

7. Potential Risks / Side Effects

Experimental

  • Injection site irritation
  • Water retention
  • Potential abnormal growth signaling
  • Limited human safety data
  • Unknown long-term tissue effects
  • Possible systemic growth-factor overexposure concerns

8. Half-Life

PEG-MGF is commonly discussed as having a substantially prolonged half-life compared to Standard MGF.

The pegylation process extends peptide duration and allows for more sustained systemic signaling activity.

9. Storage Information

  • Store refrigerated before and after reconstitution
  • Protect from direct light exposure
  • Avoid repeated freeze-thaw cycles
  • Maintain sterile handling practices during preparation

10. Contraindications / Warnings

  • Active cancer concerns
  • Uncontrolled metabolic disorders
  • Pregnancy or breastfeeding
  • Known hypersensitivity to peptide compounds
  • Use alongside multiple growth-factor compounds without supervision

11. Research References

  • PubMed
  • NIH Publications
  • Exercise physiology literature
  • Peer-reviewed growth-factor and recovery journals